IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.

Articles tagged with “dopamine-d1-antagonist”

Teva Emalex Acquisition: Ecopipam for Tourette Syndrome

Review Teva's $700M acquisition of Emalex Biosciences. Explore how ecopipam, a dopamine D1 antagonist, advances pediatric Tourette syndrome and CNS therapies.

45 min read

5/8/2026

teva pharmaceuticals emalex biosciences ecopipam tourette syndrome dopamine d1 antagonist cns therapeutics pediatric tics neurodevelopmental disorders